14.60
-0.78(-5.07%)
Currency In NaN
| Previous Close | 15.38 |
| Open | 15.56 |
| Day High | 15.56 |
| Day Low | 14.17 |
| 52-Week High | 29.74 |
| 52-Week Low | 6.43 |
| Volume | 130,651 |
| Average Volume | 172,145 |
| Market Cap | 532.86M |
| PE | -3.82 |
| EPS | -3.82 |
| Moving Average 50 Days | 11.26 |
| Moving Average 200 Days | 15.42 |
| Change | -0.78 |
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
GlobeNewswire Inc.
Jun 02, 2025 6:45 PM GMT
Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled and on track for topline results in September 2025BOSTON and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”),
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
May 27, 2025 11:00 AM GMT
BOSTON and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological
Rapport Therapeutics to Host 2025 Investor and Analyst Day
GlobeNewswire Inc.
May 21, 2025 11:00 AM GMT
BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological